A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
- Summary
- This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the safety and immunogenicity of SCTV01E in population of different ages who have been vaccinated against COVID-19. A total of 750 participants ≥3 years old who have received the recommended dose and immunization procedure of domestically approved COVID-19 vaccines will be enrolled, including 250 participants ≥18 years old (group A), 250 participants aged 12-17 years old (group B), and 250 participants aged 3-11 years old (group C). The study will be carried out gradually according to the age of the participants from older to younger. Considering that SCTV01E in this study is the first clinical study in participants under 18 years old, 15 sentinel participants will be assigned to group B and 30 sentinel participants will be assigned to group C (including 15 aged 6-11 years old and 15 aged 3-5 years old). The Primary end points are 1. The incidence and severity of solicited adverse events on days 0-7 after inoculation with SCTV01E. 2. IgG total antibody concentrations (ELISA) against SARS-CoV-2 prototype strains and neutralizing antibodies titer (Live virus neutraliztion antibody test) against SARS-CoV-2 Omicron variant at 28 days post-vaccination.
- Acronym
- SCTV01E
- Short title
- A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
- Official title
- Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants S Trimer Protein Vaccine (SCTV01E) in a Vaccinated Population
- Control arm
- Placebo
- Registry reports results
- Listing at source
- Listed
- Recruitment status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Completion date
- 2024-01-15
- First posted
- 2022-12-15
- Registry last updated
- 2024-02-08
- Primary completion date
- 2024-01-15
- Start date
- 2023-01-05
- Actual participants
- Participants
- Participant count basis
- Actual
- Protocol amendments
- Randomisation ratio
- Number of sites
- Data monitoring committee
- Registry sponsor category
- Industry
- Lead sponsor
- Sinocelltech Ltd.
- Source registry
- ClinicalTrials.gov
- Registry ID
- NCT05652543
- ClinicalTrials.gov ID
- NCT05652543
- Registry record
- Open registry record
- Allocation
- Randomised
- Model
- Parallel groups
- Purpose
- Prevention
- Masking
- Quadruple masking
- Masked roles
- Participants, Care providers, Investigators, Outcome assessors
Safety endpoint: Incidence and severity of Solicited Adverse Events
Timeframe: Day 0~Day 7
The incidence and severity of solicited adverse events on days 0-7 after inoculation with SCTV01E;
Immunogenicity endpoint 1: IgG total antibody concentration (ELISA)
Timeframe: Day 28
IgG total antibody (ELISA) concentrations against SARS-CoV-2 prototype strains at 28 days post-vaccination and serum response rates (Geometric mean concentration \[GMC\], VOC/VOI based on epidemic variations can be tested);
Immunogenicity endpoint 2: Neutralizing antibody titer against SARS-CoV-2 Omicron variants (live virus neutralization test)
Timeframe: Day 28
Geometric mean titer (GMT) and serum response rates at 28 days post-vaccination for neutralizing antibodies against SARS-CoV-2 Omicron variants (live virus neutralization test). VOC/VOI based on epidemic variations can be tested;
Safety endpoint 1: Incidence and severity of Unsolicited Adverse Events
Timeframe: Day 0~Day 28
Incidence and severity of unsolicited adverse events on days 0-28 after inoculation with SCTV01E;
Safety endpoint 2: Incidence and severity of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
Timeframe: Day 0~Day 180
Incidence and severity of serious adverse events (SAEs) and adverse events of special interest (AESIs) within 180 days of vaccination with SCTV01E.
Immunogenicity endpoint 1: IgG total antibody concentration (ELISA)
Timeframe: Day 0~Day 180
GMC and serum response rates of total IgG antibody (ELISA) against the prototype strain of SARS-CoV-2 on days 7, 14, 90 and 180 after inoculation with SCTV01E (other VOC/VOI can be increased depending on the epidemic situation);
Immunogenicity endpoint 2: Neutralizing antibody titer against SARS-CoV-2 Omicron variants (live virus neutralization test)
Timeframe: Day 0~Day 180
GMT and serum response rates for neutralizing antibodies against SARS-CoV-2 Omicron variant (live virus neutralization test) on days 7, 14, 90 and 180 after inoculation with SCTV01E (other VOC/VOI can be tested depending on the epidemic situation);
Immunogenicity endpoint 3: T cell Response
Timeframe: Day 0~Day 90
Number of T cell subsets secreting IFN-γ (for Th1) and IL-4 (for Th2) on day 7 and day 90 after SCTV01E in subjects ≥18 years old.
- Sex
- All
- Age groups
- Children, Adults, Older adults
- Minimum age
- 3 Years
- Maximum age
- 120 Years
- Healthy volunteers
- Yes
- The age when signing ICF should meet the requirements of the scheme (Group A ≥18 years old; Group B 12-17 years old; Group C, 3-11 years old) male or female;
- Have previously received the recommended dose and immunization procedures of COVID-19 vaccine approved for domestic market, and the interval between signing ICF and receiving the last dose of COVID-19 vaccine is 6-24 months;
- Subject and/or guardian or client of both parties are able to sign a written ICF and voluntarily participate in the trial, fully understand the trial procedure, the risks of participating in the trial and the alternative interventions available to non-participants;
- The subject and/or the guardian or client of both parties can read, understand and fill in the diary card;
- Healthy subjects or subjects with stable underlying diseases. Stable underlying diseases were defined as those who were in stable condition at least 3 months before inclusion in the study, had no significant change in treatment regimen and had not been admitted to hospital due to disease progression;
- Fertile men and women of childbearing age voluntarily agree to take effective contraceptive measures from signing the ICF to 180 days after receiving the trial vaccine; Pregnancy tests for women of childbearing age during the screening period were negative.
- Fever (> 14 years of age, axillary temperature ≥37.3℃; ≤14 years old, axillary temperature ≥37.5℃);
- SARS-CoV-2 nucleic acid test was positive during the screening period;
- Previous history of allergy to any vaccine or drug, such as: allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, angioneurotic edema, etc.;
- Those who have a history of immune deficiency diseases, major organ diseases, immune diseases [including Guillain-Barre syndrome (GBS), systemic lupus erythematosus, rheumatoid arthritis, asthenia or splenectomy caused by any circumstances, and other immune diseases that researchers believe may have an impact on the immune response], etc.;
- Currently suffering from severe or uncontrollable cardiovascular diseases, endocrine diseases, diseases of the blood and lymphatic systems, diseases of the liver and kidney, diseases of the respiratory system, diseases of the metabolic and skeletal systems or malignancies (other than basal cell carcinoma of the skin and carcinoma in situ of the cervix), such as severe heart failure, severe pulmonary heart disease, unstable angina, liver failure or uremia;
- The subjects are in an acute state of disease, such as acute onset of chronic heart failure, acute sore throat, hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis, etc.;
- Anti-tuberculosis therapy is being used;
- Influenza vaccine within 14 days prior to vaccination or another type of vaccine within 28 days prior to vaccination;
- Use of immunosuppressant or immunomodulatory drugs for ≥14 days in the 6 months before enrollment, but short-term use of oral, inhaled and topical steroid hormones (≤14 days) is allowed;
- are pregnant or breastfeeding or plan to become pregnant during the study period;
- HIV-positive patients;
- Lianshui County Center for Disease Control and PreventionLianshui, China
- Jiangsu Center for Disease Control and PreventionNanjing, China
- Taizhou Vaccine Clinical Research CenterTaizhou, China
- Dazhu County Center for Disease Control and PreventionDazhou, China
- PubMed 35772405Background
- Publication recorded without a publication identifierBackground
- Publication recorded without a publication identifierBackground
- Publication recorded without a publication identifierBackground
- Publication recorded without a publication identifierBackground
- Publication recorded without a publication identifierBackground
- Publication recorded without a publication identifierBackground
Related records
Drugs (1)
Lead sponsors (1)
Conditions (1)
- COVID-19 Primary condition